Stephanie L. Sherman

Stephanie L. Sherman

Auto-generated profile, based on publicly available information

Stephanie L. Sherman

Department of Human Genetics, School of Medicine, Emory University, Atlanta, GA 30322, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2009 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
RCReshmi Chowdhury
Reshmi Chowdhury
PBPhilippe R. J. Bois
Philippe R. J. Bois
EFEleanor Feingold
Eleanor Feingold
SSStephanie L. Sherman
Stephanie L. Sherman
VCVivian G. Cheung
Vivian G. Cheung
The number of recombination events per meiosis varies extensively among individuals. This recombination phenotype differs between female and male, and also among individuals of each gender. In this study, we used high-density SNP genotypes of over 2,300 individuals and their offspring in two datasets to characterize recombination landscape and to map the genetic variants that contribute to variation in recombination phenotypes. We found six genetic loci that are associated with recombination phenotypes. Two of these (RNF212 and an inversion on chromosome 17q21.31) were previously reported in the Icelandic population, and this is the first replication in any other population. Of the four newly identified loci (KIAA1462, PDZK1, UGCG, NUB1), results from expression studies provide support for their roles in meiosis. Each of the variants that we identified explains only a small fraction of the individual variation in recombination. Notably, we found different sequence variants associated with female and male recombination phenotypes, suggesting that they are regulated by different genes. Characterization of genetic variants that influence natural variation in meiotic recombination will lead to a better understanding of normal meiotic events as well as of non-disjunction, the primary cause of pregnancy loss. Meiotic recombination is essential for the formation of human gametes and is a key process that generates genetic diversity. Given its importance, we would expect the number and location of exchanges to be tightly regulated. However, studies show significant gender and inter-individual variation in genome-wide recombination rates. The genetic basis for this variation is poorly understood. In this study, we used genotypes from high-density single nucleotide polymorphism (SNP) markers of 2,315 individuals and their children from two Caucasian samples in a genome-wide association study to identify genetic variants that influence the number of meiotic recombination events per gamete. We found three loci that influence female recombination and three different loci that influence male recombination. Our results suggest that gender differences in recombination result from differences in the genetic regulation of female and male meiosis. Also, each identified locus only explains a small proportion of variance; together, each set of loci explains about 10% of the variation in the gender-specific recombination phenotype. This suggests a mechanism for variability in recombination that is essential for genetic diversity while maintaining the number of recombinations within a range to ensure proper chromosome segregation.

30 July 2014 in Journal of Neurodevelopmental Disorders
Verified
Journal Article
Open access
PDF file
AWAnne Wheeler
Anne Wheeler
DBDonald Bailey
Donald Bailey
EBElizabeth M. NA Berry-Kravis
Elizabeth M. NA Berry-Kravis
JGJan Greenberg
Jan Greenberg
MLMolly Losh
Molly Losh
RHRandi Hagerman
Randi Hagerman
Changes in the fragile X mental retardation 1 gene (FMR1) have been associated with specific phenotypes, most specifically those of fragile X syndrome (FXS), fragile X tremor/ataxia syndrome (FXTAS), and fragile X primary ovarian insufficiency (FXPOI). Evidence of increased risk for additional medical, psychiatric, and cognitive features and conditions is now known to exist for individuals with a premutation, although some features have been more thoroughly studied than others. This review highlights the literature on medical, reproductive, cognitive, and psychiatric features, primarily in females, that have been suggested to be associated with changes in the FMR1 gene. Based on this review, each feature is evaluated with regard to the strength of evidence of association with the premutation. Areas of need for additional focused research and possible intervention strategies are suggested.

30 July 2014 in Journal of Neurodevelopmental Disorders
Verified
Journal Article
Open access
PDF file
JGJim Grigsby
Jim Grigsby
KCKim Cornish
Kim Cornish
DHDarren Robert Hocking
Darren Robert Hocking
CKClaudine Kraan
Claudine Kraan
JOJohn Olichney
John Olichney
JYJin-Chen Yang
Jin-Chen Yang
The fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder affecting a subset of carriers of the FMR1 (fragile X mental retardation 1) premutation. Penetrance and expression appear to be significantly higher in males than females. Although the most obvious aspect of the phenotype is the movement disorder that gives FXTAS its name, the disorder is also accompanied by progressive cognitive impairment. In this review, we address the cognitive neuropsychological and neurophysiological phenotype for males and females with FXTAS, and for male and female unaffected carriers. Despite differences in penetrance and expression, the cognitive features of the disorder appear similar for both genders, with impairment of executive functioning, working memory, and information processing the most prominent. Deficits in these functional systems may be largely responsible for impairment on other measures, including tests of general intelligence and declarative learning. FXTAS is to a large extent a white matter disease, and the cognitive phenotypes observed are consistent with what some have described as white matter dementia, in contrast to the impaired cortical functioning more characteristic of Alzheimer’s disease and related disorders. Although some degree of impaired executive functioning appears to be ubiquitous among persons with FXTAS, the data suggest that only a subset of unaffected carriers of the premutation - both female and male - demonstrate such deficits, which typically are mild. The best-studied phenotype is that of males with FXTAS. The manifestations of cognitive impairment among asymptomatic male carriers, and among women with and without FXTAS, are less well understood, but have come under increased scrutiny.

29 January 2011 in neurogenetics
Verified
Journal Article
Closed access
PDF file
JJJorge L. Juncos
Jorge L. Juncos
JLJoash T. Lazarus
Joash T. Lazarus
EGEmily Graves-Allen
Emily Graves-Allen
LSLisa Shubeck
Lisa Shubeck
MRMichelle Rusin
Michelle Rusin
SSStephanie L. Sherman
Stephanie L. Sherman

1 December 2008 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
JHJessica Ezzell Hunter
Jessica Ezzell Hunter
EAEmily Graves Allen
Emily Graves Allen
AAAnn Abramowitz
Ann Abramowitz
MRMichele Rusin
Michele Rusin
MLMary Leslie
Mary Leslie
SSStephanie L. Sherman
Stephanie L. Sherman

13 August 2014 in Journal of Neurodevelopmental Disorders
Verified
Journal Article
Open access
PDF file
SSStephanie L Sherman
Stephanie L Sherman
ECEliza C Curnow
Eliza C Curnow
CECharles A Easley
Charles A Easley
PJPeng Jin
Peng Jin
RHRenate K Hukema
Renate K Hukema
KUKaren Usdin
Karen Usdin
Fragile X-associated primary ovarian insufficiency (FXPOI) is among the family of disorders caused by the expansion of a CGG repeat sequence in the 5' untranslated region of the X-linked gene FMR1. About 20% of women who carry the premutation allele (55 to 200 unmethylated CGG repeats) develop hypergonadotropic hypogonadism and cease menstruating before age 40. Some proportion of those who are still cycling show hormonal profiles indicative of ovarian dysfunction. FXPOI leads to subfertility and an increased risk of medical conditions associated with early estrogen deficiency. Little progress has been made in understanding the etiology of this clinically significant disorder. Understanding the molecular mechanisms of FXPOI requires a detailed knowledge of ovarian FMR1 mRNA and FMRP’s function. In humans, non-invasive methods to discriminate the mechanisms of the premutation on ovarian function are not available, thus necessitating the development of model systems. Vertebrate (mouse and rat) and invertebrate (Drosophila melanogaster) animal studies for the FMR1 premutation and ovarian function exist and have been instrumental in advancing our understanding of the disease phenotype. For example, rodent models have shown that FMRP is highly expressed in oocytes where it is important for folliculogenesis. The two premutation mouse models studied to date show evidence of ovarian dysfunction and, together, suggest that the long repeat in the transcript itself may have some pathological effect quite apart from any effect of the toxic protein. Further, ovarian morphology in young animals appears normal and the primordial follicle pool size does not differ from that of wild-type animals. However, there is a progressive premature decline in the levels of most follicle classes. Observations also include granulosa cell abnormalities and altered gene expression patterns. Further comparisons of these models are now needed to gain insight into the etiology of the ovarian dysfunction. Premutation model systems in non-human primates and those based on induced pluripotent stem cells show particular promise and will complement current models. Here, we review the characterization of the current models and describe the development and potential of the new models. Finally, we will discuss some of the molecular mechanisms that might be responsible for FXPOI.